These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23553917)

  • 41. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Kang M; Reynolds CP; Wu J; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Lock R; Kolb EA; Gorlick R; Keir ST; Carol H; Morton CL; Reynolds CP; Kang MH; Houghton PJ
    Pediatr Blood Cancer; 2011 Aug; 57(2):268-74. PubMed ID: 21360650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
    Houghton PJ; Kurmasheva RT; Lyalin D; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2014 Nov; 61(11):1972-9. PubMed ID: 25131802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
    Kurmasheva RT; Reynolds CP; Kang MH; Allievi C; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 May; 61(5):922-4. PubMed ID: 24166988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
    Houghton PJ; Lock R; Carol H; Morton CL; Gorlick R; Anders Kolb E; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups CA; Zhang MX; Madden SL; Teicher BA; Smith MA
    Pediatr Blood Cancer; 2012 Feb; 58(2):200-9. PubMed ID: 21548007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
    Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of ABT-751 against childhood cancer models in vivo.
    Morton CL; Favours EG; Mercer KS; Boltz CR; Crumpton JC; Tucker C; Billups CA; Houghton PJ
    Invest New Drugs; 2007 Aug; 25(4):285-95. PubMed ID: 17384918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
    Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Apr; 58(4):636-9. PubMed ID: 21681929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
    Thara E; Gitlitz BJ
    Future Oncol; 2014 Oct; 10(12):1913-24. PubMed ID: 25386810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
    Morton CL; Houghton PJ; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Aug; 55(2):295-303. PubMed ID: 20582972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
    Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
    Takahashi M; Miki S; Fujimoto K; Fukuoka K; Matsushita Y; Maida Y; Yasukawa M; Hayashi M; Shinkyo R; Kikuchi K; Mukasa A; Nishikawa R; Tamura K; Narita Y; Hamada A; Masutomi K; Ichimura K
    Cancer Sci; 2019 Jul; 110(7):2247-2257. PubMed ID: 31099446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.
    De Vita A; Miserocchi G; Recine F; Mercatali L; Pieri F; Medri L; Bongiovanni A; Cavaliere D; Liverani C; Spadazzi C; Amadori D; Ibrahim T
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27918490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.
    Gorlick R; Maris JM; Houghton PJ; Lock R; Carol H; Kurmasheva RT; Kolb EA; Keir ST; Reynolds CP; Kang MH; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Sep; 59(3):518-24. PubMed ID: 22102563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
    Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
    Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.